PTC Therapeutics Dividend
Dividend criteriumcontroles 0/6
PTC Therapeutics does not have a record of paying a dividend.
Belangrijke informatie
n/a
Dividendrendement
-0.4%
Terugkoop Rendement
Totaal aandeelhoudersrendement | -0.4% |
Toekomstig dividendrendement | 0% |
Dividendgroei | n/a |
Volgende betaaldatum dividend | n/a |
Ex-dividenddatum | n/a |
Dividend per aandeel | n/a |
Uitbetalingsratio | n/a |
Recente dividendupdates
Geen updates
Recent updates
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth
Oct 09PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value
Sep 12Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues
Jun 28PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna
May 22Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%
May 22PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts
May 14PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Mar 03PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options
Feb 11An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued
Jun 23Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price
May 18An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued
Mar 02PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.
Oct 19PTC Therapeutics betas topline expectations, strengthens commercial portfolio
Aug 05PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder
Jul 20PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price
Jun 24Are PTC Therapeutics, Inc. (NASDAQ:PTCT) Investors Paying Above The Intrinsic Value?
May 27Stabiliteit en groei van betalingen
Dividenden ophalen
Stabiel dividend: Insufficient data to determine if PTCT's dividends per share have been stable in the past.
Groeiend dividend: Insufficient data to determine if PTCT's dividend payments have been increasing.
Dividendrendement versus markt
PTC Therapeutics Dividendrendement versus markt |
---|
Segment | Dividendrendement |
---|---|
Bedrijf (PTCT) | n/a |
Markt onderkant 25% (US) | 1.5% |
Markt Top 25% (US) | 4.5% |
Gemiddelde industrie (Biotechs) | 2.2% |
Analist prognose (PTCT) (tot 3 jaar) | 0% |
Opmerkelijk dividend: Unable to evaluate PTCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Hoog dividend: Unable to evaluate PTCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Winstuitkering aan aandeelhouders
Verdiendekking: Insufficient data to calculate PTCT's payout ratio to determine if its dividend payments are covered by earnings.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: Unable to calculate sustainability of dividends as PTCT has not reported any payouts.